At the news
? NEUTRALIMPACT 5/10 8-K filed Aug 10, 2026 at 07:20 ET
Silence Therapeutics reported Q2 2026 net loss of $12.3M ($0.09 per share), narrower than the $27.4M loss in Q2 2025 and ahead of the $0.11 consensus. Cash burn slowed as R&D costs dropped 48% YoY to $9.1M. The key catalyst is the upcoming Phase 2 SANRECO topline readout for divesiran in polycythemia vera expected in August 2026, which will determine the stock's near-term trajectory.
- Net loss of $12.3M ($0.09/share) vs $27.4M ($0.19/share) in Q2 2025, narrower loss beats consensus of $0.11 loss
- Revenue $0.2M vs $0.4M in Q2 2025 (AstraZeneca collaboration), no consensus revenue figure available for comparison
- Cash and cash equivalents $72.1M as of June 30, 2026, up from $11.3M at Dec 31, 2025 (no new financings cited; likely reflects timing of R&D benefit receivable and cash burn)
- R&D expenses fell 48% YoY to $9.1M (from $17.6M) due to zerlasiran Phase 3 readiness completion and reduced personnel costs
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access